Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion
Executive Summary
BARCELONA, SPAIN - For companies looking to adopt adaptive trial designs, Merck VP of Biostatistics and Research Decision Sciences Jerald Schindler urged sponsors to frontload most of the adaptation in the non-pivotal portion of the clinical trial program and limit their own involvement in the adaptation that does take place during the pivotal portion
You may also be interested in...
Sponsors’ Use Of Adaptive Designs Appears To Be Growing
A Drug Information Association working group survey found 477 studies between Jan. 1, 2008 and Sept. 1, 2011 utilized some type of adaptive design.
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Sponsors should take care that drug development efficiencies gained with the advent of adaptive clinical trials aren't offset by lack of opportunity to reflect on data from one trial to the next and "design a thoughtful, complete program," FDA warns in its draft guidance for adaptive trial design
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Sponsors should take care that drug development efficiencies gained with the advent of adaptive clinical trials aren't offset by lack of opportunity to reflect on data from one trial to the next and "design a thoughtful, complete program," FDA warns in its draft guidance for adaptive trial design